ABBV-154 for Crohn's Disease (AIM-CD Trial)

"ABBV-154 is currently being assessed for safety in Phase 2 trials, meaning there are several rounds of data confirming its level of risk. Consequently, Power has rated ABBV-154's security as a 2 on a scale from 1 to 3."

"This trial is seeking 265 individuals aged 18 to 75 with a confirmed diagnosis of ileocolitis. In addition, applicants must satisfy the following: Possess Crohn's disease (CD) for at least 3 months before Baseline of Induction Period., Have CDAI score of 220 to 450 at beginning of Induction Phase., Exhibit endoscopic evidence of mucosal inflammation through SES-CD >=6 if suffering from colonic or ileal colonic diseases and SES-CD >=4 for isolated ileal conditions as examined by an unbiased observer., Displayed inefficacy towards biologic agents such as inflixim"

"The prerequisites for enrolment in this research indicates that participants must be between 18 and 75 years of age. For those below the age of consent, there are 69 studies available; conversely, 194 studies cater to adults above 65."

"According to the latest figures from clinicaltrials.gov, this research project is actively recruiting volunteers. The trial was originally published on January 31st 2022 and last updated on November 21st of that same year."

"Currently, there are 70 trial sites participating in this research. A few of the most notable ones include University of Utah Hospitals and Clinics (ID# 239264) located in Salt Lake City, GI Specialists of GA PC (ID#239261) situated in Marietta, Georgia and Allegheny Health Network Research Institute (ID #239334) based out of Pittsburgh, Pennsylvania."

"265 eligible patients must join this study. Participation is available in University of Utah Hospitals and Clinics (ID# 239264) located Salt Lake City, UT or GI Specialists of GA, PC /ID# 239261 situated in Marietta, GA."